Abstract:Circulation: Genomic and Precision Medicine, Ahead of Print. BACKGROUND:Interpretation of variants of uncertain significance (VUSs) remains a challenge in the care of patients with inherited cardiovascular diseases (CVDs); 56% of variants within CVD risk genes are VUS, and machine learning algorithms trained upon large data resources can stratify VUS into higher versus lower probability of contributing to a CVD phenotype.METHODS:We used ClinVar pathogenic/likely pathogenic and benign/likely benign variants from 47 CVD genes to build a predictive model of variant pathogenicity utilizing measures of evolutionary constraint, deleteriousness, splicogenicity, local pathogenicity, cardiac-specific expression, and population allele frequency. Performance was validated using variants for which the ClinVar pathogenicity assignment changed. Functional validation was assessed using prior studies in >900 identified VUS. The model utility was demonstrated using the Catheterization Genetics cohort.RESULTS:We identified a top-ranked model that accurately prioritized variants for which ClinVar clinical significance had changed (n=663; precision-recall area under the curve, 0.97) and performed well compared with conventional in silico methods. This model (CVD pathogenicity predictor) also had high accuracy in prioritizing VUS with functional effects in vivo (precision-recall area under the curve, 0.58). In Catheterization Genetics, there was a greater burden of higher CVD pathogenicity predictor scored VUS in individuals with dilated cardiomyopathy compared with controls (P=8.2×10−15). Of individuals in Catheterization Genetics who harbored highly ranked CVD pathogenicity predictor VUS meeting clinical pathogenicity criteria, 27.6% had clinical evidence of disease. Variant prioritization using this model increased genetic diagnosis in Catheterization Genetics participants with a known clinical diagnosis of hypertrophic cardiomyopathy (7.8%–27.2%).CONCLUSIONS:We present a cardiac-specific model for prioritizing variants underlying CVD syndromes with high performance in discriminating the pathogenicity of VUS in CVD genes. Variant review and phenotyping of individuals carrying VUS of pathogenic interest support the clinical utility of this model. This model could also have utility in filtering variants as part of large-scale genomic sequencing studies.

VarPPUD: Variant post prioritization developed for undiagnosed genetic disorders

A Robust Phenotype-Driven Likelihood Ratio Analysis Approach Assisting Interpretable Clinical Diagnosis of Rare Diseases.

Cardiovascular Disease Pathogenicity Predictor (CVD-PP): A Tissue-Specific In Silico Tool for Discriminating Pathogenicity of Variants of Unknown Significance in Cardiovascular Disease Genes

Improved diagnosis of rare disease patients through application of constrained coding region annotation and de novo status.

Prioritizing Genomic Variants Pathogenicity Via DNA, RNA, and Protein-Level Features Based on Extreme Gradient Boosting

PERCH: A Unified Framework for Disease Gene Prioritization

Predicting the Occurrence of Variants in RAG1 and RAG2

De novo pattern discovery enables robust assessment of functional consequences of non-coding variants

PSAP‐Genomic‐Regions: A Method Leveraging Population Data to Prioritize Coding and Non‐Coding Variants in Whole Genome Sequencing for Rare Disease Diagnosis

Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort

An AI-based approach driven by genotypes and phenotypes to uplift the diagnostic yield of genetic diseases

VPatho: a deep learning-based two-stage approach for accurate prediction of gain-of-function and loss-of-function variants

PSAP-genomic-regions: a method leveraging population data to prioritize coding and non-coding variants in whole genome sequencing for rare disease diagnosis

Improved Detection of Rare Genetic Variants for Diseases

Joint, multifaceted genomic analysis enables diagnosis of diverse, ultra-rare monogenic presentations

Regsnps: a Strategy for Prioritizing Regulatory Single Nucleotide Substitutions.

Efficient Utilization of Rare Variants for Detection of Disease-Related Genomic Regions

GenePANDA—a Novel Network-Based Gene Prioritizing Tool for Complex Diseases

Decoding polygenic diseases: advances in noncoding variant prioritization and validation

A Novel Statistical Method for Interpreting the Pathogenicity of Rare Variants